{"analyses":[{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.90"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.78","upperLimit":"12.06","value":"8.38"},{"groupId":"OG001","lowerLimit":"6.47","upperLimit":"8.44","value":"7.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"Randomization to first documented tumor progression or death due to any cause, whichever occurred first. Participants who die without reported prior progression are considered to have progressed on date of their death. Participants who did not progress or die will be censored at their last efficacy assessment. Participants who did not have on study efficacy assessments and alive will be censored on randomization date. Participants who started subsequent anti-cancer therapy without prior reported progression will be censored at last efficacy assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), \\>/= 50% increase from nadir in SPD of \\> 1 lesion, or \\>/= 50% increase in the longest diameter of a previous lesion \\> 1 cm in short axis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG000","title":"Arm A: N-Pd"},{"description":"Pomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG001","title":"Arm B: Pd"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and B. Data was pre-specified to be collected only in the N-Pd and Pd arms.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of the first documented tumor progression or death due to any cause, whichever occurred first (Up to approximately 64 month)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}